Allogene Therapeutics Inc (NASDAQ: ALLO) is -15.26% lower on its value in year-to-date trading and has touched a low of $2.01 and a high of $5.78 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ALLO stock was last observed hovering at around $2.62 in the last trading session, with the day’s gains setting it 0.1%.
Currently trading at $2.72, the stock is 0.93% and 1.01% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.93 million and changing 3.82% at the moment leaves the stock -15.66% off its SMA200. ALLO registered -19.05% loss for a year compared to 6-month loss of -39.01%. The firm has a 50-day simple moving average (SMA 50) of $2.6788 and a 200-day simple moving average (SMA200) of $3.22645.
The stock witnessed a 1.49% gain in the last 1 month and extending the period to 3 months gives it a 11.48%, and is -6.53% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.32% over the week and 7.95% over the month.
Allogene Therapeutics Inc (ALLO) has around 233 employees, a market worth around $568.78M and $0.09M in sales. Profit margin for the company is -323780.23%. Distance from 52-week low is 35.32% and -52.90% from its 52-week high. The company has generated returns on investments over the last 12 months (-46.25%).
The EPS is expected to grow by 32.39% this year
243.0 institutions hold shares in Allogene Therapeutics Inc (ALLO), with institutional investors hold 97.78% of the company’s shares. The shares outstanding are 167.13M, and float is at 136.57M with Short Float at 28.69%. Institutions hold 80.69% of the Float.
The top institutional shareholder in the company is FMR LLC with over 31.26 million shares valued at $72.83 million. The investor’s holdings represent 18.4816 of the ALLO Shares outstanding. As of 2024-06-30, the second largest holder is TPG GP A, LLC with 18.72 million shares valued at $43.61 million to account for 11.0663 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 16.45 million shares representing 9.7238 and valued at over $38.32 million, while VANGUARD GROUP INC holds 4.8458 of the shares totaling 8.2 million with a market value of $19.1 million.
Allogene Therapeutics Inc (ALLO) Insider Activity
Allogene Therapeutics Inc disclosed in a document filed with the SEC on Jun 18 ’24 that MESSEMER DEBORAH M. (Director) sold a total of 18,641 shares of the company’s common stock. The trade occurred on Jun 18 ’24 and was made at $2.28 per share for $42488.0. Following the transaction, the insider now directly holds 0.17 million shares of the ALLO stock.
Still, SEC filings show that on May 30 ’24, Humer Franz B (Director) disposed off 11,200 shares at an average price of $2.34 for $26181.0. The insider now directly holds 255,253 shares of Allogene Therapeutics Inc (ALLO).
